Brief: Pharnext: High-Dose Pxt3003 Showed Improvement In Primary Endpoint

Pharnext SCA

18/10/2021 17:12

Oct 18 (Reuters) - Pharnext SA  PHARN.PA :
    * DATA FROM FIRST PHASE III CLINICAL STUDY OF PXT3003 IN
CHARCOT-MARIE-TOOTH DISEASE TYPE 1A, THE PLEO-CMT TRIAL,
PUBLISHED IN THE ORPHANET JOURNAL OF RARE DISEASES
    * HIGH-DOSE PXT3003 GROUP SHOWED A SIGNIFICANT IMPROVEMENT
IN
PRIMARY ENDPOINT, ONLS SCALE, VERSUS PLACEBO
    * AUTHORS STATE HIGH-DOSE PXT3003 IS CONSIDERED A PROMISING
TREATMENT OPTION FOR PATIENTS WITH CMT1A
    * DESPITE PROMISING EFFICACY AND SAFETY DATA OBTAINED IN
PLEO-CMT
TRIAL, U.S. FDA AND EMA HAVE REQUESTED A SECOND PHASE III
CLINICAL STUDY

Source text for Eikon:  ID:nEQ9CPzPma 
Further company coverage:  PHARN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))